Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
British Journal of Haematology|August 26, 2004
Unrelated cord blood transplantation after myeloablative conditioning in patients over the age of 45 yearsJun Ooi, Tohru Iseki, Satoshi Takahashi, et al.
International Journal of Hematology|May 16, 2022
Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysisKihyun Kim, Chang-Ki Min, Youngil Koh, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 21, 2023
Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup AnalysisYawara Kawano, Kihyun Kim, Chang Ki Min, et al.
International Journal of Hematology|September 2, 2020
Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patientsKen Ishiyama, Shinji Nakao, Kensuke Usuki, et al.
European Journal of Haematology|November 13, 2024
Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE StudiesAlexander Röth, Rong Fu, Guangsheng He, et al.
Hematological Oncology|November 26, 2022
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs studyKazutaka Sunami, Shin-Ichi Fuchida, Kenshi Suzuki, et al.
Cancer Science|September 25, 2020
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy studyKazutaka Sunami, Kenshi Suzuki, Masaki Ri, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2022
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup AnalysisKazutaka Sunami, Takashi Ikeda, Shang-Yi Huang, et al.
The New England Journal of Medicine|March 13, 2024
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal HemoglobinuriaRégis Peffault de Latour, Alexander Röth, Austin G Kulasekararaj, et al.
The Lancet. Haematology|May 30, 2025
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitorsAntonio M Risitano, Austin G Kulasekararaj, Phillip Scheinberg, et al.
Pageof 3